image
Healthcare - Biotechnology - NASDAQ - US
$ 0.7225
-3.36 %
$ 1.54 M
Market Cap
-0.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLRX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.723 USD, Salarius Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.723 USD, Salarius Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLRX stock under the best case scenario is HIDDEN Compared to the current market price of 0.723 USD, Salarius Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SLRX

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-5.73 M OPERATING INCOME
-44369.49%
-5.58 M NET INCOME
55.55%
-4.53 M OPERATING CASH FLOW
64.77%
0 INVESTING CASH FLOW
0.00%
1.06 M FINANCING CASH FLOW
-84.04%
0 REVENUE
0.00%
-1.71 M OPERATING INCOME
-14.83%
-1.71 M NET INCOME
-16.78%
-1.18 M OPERATING CASH FLOW
-59.15%
0 INVESTING CASH FLOW
0.00%
546 K FINANCING CASH FLOW
609.96%
Balance Sheet Salarius Pharmaceuticals, Inc.
image
Current Assets 2.99 M
Cash & Short-Term Investments 2.43 M
Receivables 0
Other Current Assets 553 K
Non-Current Assets 35.4 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 35.4 K
80.53 %18.29 %Total Assets$3.0m
Current Liabilities 1.51 M
Accounts Payable 937 K
Short-Term Debt 222 K
Other Current Liabilities 352 K
Non-Current Liabilities 352 K
Long-Term Debt 0
Other Non-Current Liabilities 352 K
50.28 %11.90 %18.91 %18.91 %Total Liabilities$1.9m
EFFICIENCY
Earnings Waterfall Salarius Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 4.42 K
Gross Profit 0
Operating Expenses 5.73 M
Operating Income -5.73 M
Other Expenses -159 K
Net Income -5.58 M
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)0(4k)0(6m)(6m)159k(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-368.84% ROE
-368.84%
-184.45% ROA
-184.45%
-330.78% ROIC
-330.78%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Salarius Pharmaceuticals, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.58 M
Depreciation & Amortization 4.42 K
Capital Expenditures 0
Stock-Based Compensation 274 K
Change in Working Capital 772 K
Others 438 K
Free Cash Flow -4.53 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Salarius Pharmaceuticals, Inc.
image
SLRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Salarius Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience globenewswire.com - 2 months ago
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer globenewswire.com - 2 months ago
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990. globenewswire.com - 4 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRX NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Salarius Pharmaceuticals, Inc. ( Nasdaq : SLRX ), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company. globenewswire.com - 5 months ago
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Salarius stockholders would own only approximately 14% of the outstanding shares and. businesswire.com - 5 months ago
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 150 points on Monday. benzinga.com - 5 months ago
Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today? Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ: SLRX ) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering recently. investorplace.com - 10 months ago
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Salarius' common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404 and the Company's existing trading symbol “SLRX.” globenewswire.com - 1 year ago
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers globenewswire.com - 1 year ago
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% globenewswire.com - 1 year ago
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months globenewswire.com - 1 year ago
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2023 and provided a business update. Financial and Business Highlights Cash and cash equivalents were $11.5 million as of June 30, 2023, compared with $12.1 million as of December 31, 2022 Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share, compared with net loss for the second quarter of 2022 of $4.7 million, or $2.20 per share, reflecting lower spending on seclidemstat and lower general and administrative expenses Raised gross proceeds of $6.0 million from a private placement of common stock and warrants, and an additional $1.7 million from an At the Market facility Announced plans to explore strategic alternatives and implement measures to extend resources “While the second quarter and recent weeks were highlighted by significant advancements in both of our development programs, after a review of each program's future funding needs and the current financial markets, the Board of Directors has made the difficult decision to limit further drug development while we explore strategic alternatives for Salarius,” said David Arthur, president and chief executive officer of Salarius Pharmaceuticals. globenewswire.com - 1 year ago
8. Profile Summary

Salarius Pharmaceuticals, Inc. SLRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.54 M
Dividend Yield 0.00%
Description Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Contact 2450 Holcombe Boulevard, Houston, TX, 77021 https://www.salariuspharma.com
IPO Date Jan. 29, 2015
Employees 2
Officers Mr. Mark J. Rosenblum CPA Executive Vice President of Finance & Chief Financial Officer Mr. David J. Arthur M.B.A. Chief Executive Officer, President & Director